Dr. Jamie L. Rhoads, M.D.

Medicare patients and services

Medicare patients, 2024

136

Services billed

777

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 17 payments worth $30,719 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Utah →

Industry-funded research

Named as a principal investigator on 19 industry-funded studies in 2025, from 8 companies. The companies reported $763,391 in research payments for these studies, mostly to the institutions running them.

• A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
  Amgen Inc.
• A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
  Pfizer Inc.
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
  AbbVie Inc. · Active, not recruiting · NCT05889182
• A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
  AbbVie Inc. · Active, not recruiting · NCT06468228
• M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
  AbbVie Inc.
• A phase 3 external and synthetic placebocontrolled randomized study with doseup for nonresponders to investigate safety and efficacy of ritlecitinib 50 mg and 100 mg once daily in adult and adolescent participants 12 …
  Pfizer Inc.
• A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ? 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)
  Amgen Inc.
• Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
  Regeneron Pharmaceuticals, Inc. · Completed · NCT04206553
• A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Murray

• Kylee Christoffersen
• Rebekah H. Clifford, MD
• Kevin W. Dahle, M.D.
• Ariana Garcia
• Allee Gerfen
• Luke S. Johnson, MD
• Jenae Laxson, LME
• Sancy A. Leachman, M.D.